了解针对 COVID-19 的 T 细胞反应对于制定公共卫生策略至关重要。
Understanding T cell responses to COVID-19 is essential for informing public health strategies.
机构信息
Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
出版信息
Sci Immunol. 2022 May 20;7(71):eabo1303. doi: 10.1126/sciimmunol.abo1303.
Abstract
Durable T cell responses to SARS-CoV-2 antigens after infection or vaccination improve immune-mediated viral clearance. To date, population-based surveys of COVID-19 adaptive immunity have focused on testing for IgG antibodies that bind spike protein and/or neutralize the virus. Deployment of existing methods for measuring T cell immunity could provide a more complete profile of immune status, informing public health policies and interventions.
摘要
感染或接种 SARS-CoV-2 抗原后，对 SARS-CoV-2 抗原的持久 T 细胞反应可改善免疫介导的病毒清除。迄今为止，基于人群的 COVID-19 适应性免疫调查主要集中在检测与刺突蛋白结合和/或中和病毒的 IgG 抗体。部署现有的 T 细胞免疫检测方法可以更全面地了解免疫状态，为公共卫生政策和干预措施提供信息。
相似文献
1
Understanding T cell responses to COVID-19 is essential for informing public health strategies.
Sci Immunol. 2022 May 20;7(71):eabo1303. doi: 10.1126/sciimmunol.abo1303.
2
Longitudinal humoral and cell-mediated immune responses in a population-based cohort in Zurich, Switzerland between March and June 2022 - evidence for protection against Omicron SARS-CoV-2 infection by neutralizing antibodies and spike-specific T-cell responses.
Int J Infect Dis. 2023 Aug;133:18-26. doi: 10.1016/j.ijid.2023.04.407. Epub 2023 May 5.
3
Long-lasting T-cell response to SARS-CoV-2 antigens after vaccination-a prospective cohort study of HCWs working with COVID-19 patients.
Infect Dis (Lond). 2023 Feb;55(2):142-148. doi: 10.1080/23744235.2022.2142662. Epub 2022 Nov 11.
4
Induction of High Levels of Specific Humoral and Cellular Responses to SARS-CoV-2 After the Administration of Covid-19 mRNA Vaccines Requires Several Days.
Front Immunol. 2021 Oct 4;12:726960. doi: 10.3389/fimmu.2021.726960. eCollection 2021.
5
T-Cell Mediated Response after Primary and Booster SARS-CoV-2 Messenger RNA Vaccination in Nursing Home Residents.
J Am Med Dir Assoc. 2023 Feb;24(2):140-147.e2. doi: 10.1016/j.jamda.2022.11.024. Epub 2022 Dec 7.
6
SARS-CoV-2 antibody and T cell responses one year after COVID-19 and the booster effect of vaccination: A prospective cohort study.
J Infect. 2022 Feb;84(2):171-178. doi: 10.1016/j.jinf.2021.12.003. Epub 2021 Dec 9.
7
High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.
Microbiol Spectr. 2021 Dec 22;9(3):e0096521. doi: 10.1128/Spectrum.00965-21. Epub 2021 Nov 10.
8
Pre-existing immunity to SARS-CoV-2 associates with strong T cell responses induced by inactivated COVID-19 vaccines.
J Med Virol. 2023 Mar;95(3):e28642. doi: 10.1002/jmv.28642.
9
Durable T-cellular and humoral responses in SARS-CoV-2 hospitalized and community patients.
PLoS One. 2022 Feb 22;17(2):e0261979. doi: 10.1371/journal.pone.0261979. eCollection 2022.
10
Cellular and humoral responses after second and third SARS-CoV-2 vaccinations in patients with autoimmune diseases treated with rituximab: specific T cell immunity remains longer and plays a protective role against SARS-CoV-2 reinfections.
Front Immunol. 2023 Apr 27;14:1146841. doi: 10.3389/fimmu.2023.1146841. eCollection 2023.
引用本文的文献
1
Vaccination, infection, and hybrid immunity: determinants of SARS-CoV-2 IgG antibody levels and protection in Quzhou, China.
Front Immunol. 2025 Jul 28;16:1576016. doi: 10.3389/fimmu.2025.1576016. eCollection 2025.
2
Vaccine-induced T cell responses correlate with reduced risk of severe COVID-19 in a placebo-controlled efficacy trial.
EBioMedicine. 2025 Jul;117:105809. doi: 10.1016/j.ebiom.2025.105809. Epub 2025 Jun 14.
3
Use of a Multiplex Immunoassay Platform to Investigate Multifaceted Antibody Responses in SARS-CoV-2 Vaccinees with and Without Prior Infection.
COVID. 2025 Apr;5(4). doi: 10.3390/covid5040044. Epub 2025 Mar 22.
4
Immunologic Response and Effects of COVID-19 Vaccines in Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Yonsei Med J. 2025 May;66(5):259-268. doi: 10.3349/ymj.2024.0129.
5
Novel Vaccines Targeting the Highly Conserved SARS-CoV-2 ORF3a Ectodomain Elicit Immunogenicity in Mouse Models.
Vaccines (Basel). 2025 Feb 22;13(3):220. doi: 10.3390/vaccines13030220.
6
Booster effect of the fourth dose of the SARS-CoV-2 mRNA vaccine in kidney transplant recipients.
Clin Exp Nephrol. 2025 Mar 11. doi: 10.1007/s10157-025-02651-6.
7
Limitations of neutralizing antibody titers in COVID-19 vaccine efficacy trials and a call for additional correlates of protection.
Hum Vaccin Immunother. 2025 Dec;21(1):2473795. doi: 10.1080/21645515.2025.2473795. Epub 2025 Mar 7.
8
A randomized, double-blind, placebo-controlled trial of IL-7 in critically ill patients with COVID-19.
JCI Insight. 2025 Feb 4;10(6):e189150. doi: 10.1172/jci.insight.189150.
9
NIAID Workshop Report: Systematic Approaches for ESKAPE Bacteria Antigen Discovery.
Vaccines (Basel). 2025 Jan 18;13(1):87. doi: 10.3390/vaccines13010087.
10
Vaccine-induced T cell responses control Orthoflavivirus challenge infection without neutralizing antibodies in humans.
Nat Microbiol. 2025 Feb;10(2):374-387. doi: 10.1038/s41564-024-01903-7. Epub 2025 Jan 10.
本文引用的文献
1
Clinical Validation of a Novel T-Cell Receptor Sequencing Assay for Identification of Recent or Prior Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
Clin Infect Dis. 2022 Dec 19;75(12):2079-2087. doi: 10.1093/cid/ciac353.
2
Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa.
Science. 2022 May 6;376(6593):eabn4947. doi: 10.1126/science.abn4947.
3
Humoral and T-cell responses to SARS-CoV-2 vaccination in multiple sclerosis patients treated with ocrelizumab.
Mult Scler Relat Disord. 2022 Jan;57:103382. doi: 10.1016/j.msard.2021.103382. Epub 2021 Nov 9.
4
T cell responses to SARS-CoV-2 spike cross-recognize Omicron.
Nature. 2022 Mar;603(7901):488-492. doi: 10.1038/s41586-022-04460-3. Epub 2022 Jan 31.
5
Cross-reactive memory T cells associate with protection against SARS-CoV-2 infection in COVID-19 contacts.
Nat Commun. 2022 Jan 10;13(1):80. doi: 10.1038/s41467-021-27674-x.
6
SARS-CoV-2 spreads through cell-to-cell transmission.
Proc Natl Acad Sci U S A. 2022 Jan 4;119(1). doi: 10.1073/pnas.2111400119.
7
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial.
Lancet. 2021 Dec 18;398(10318):2258-2276. doi: 10.1016/S0140-6736(21)02717-3. Epub 2021 Dec 2.
8
Evidence of SARS-CoV-2-Specific Memory B Cells Six Months After Vaccination With the BNT162b2 mRNA Vaccine.
Front Immunol. 2021 Sep 28;12:740708. doi: 10.3389/fimmu.2021.740708. eCollection 2021.
9
mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern.
Science. 2021 Dec 3;374(6572):abm0829. doi: 10.1126/science.abm0829.
10
Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months.
N Engl J Med. 2021 Dec 9;385(24):e84. doi: 10.1056/NEJMoa2114583. Epub 2021 Oct 6.
Zotero 插件